TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Total Non-current Assets

All assets not expected to be converted to cash within one year.

TG Therapeutics, Inc.NASDAQ: TGTX

Total Non-current Assets · Q3 FY2026 · quarter ended Sep 2026

Total non-current assets broadly unchanged from a year ago

Total non-current assets stood at $420.81M at the end of Q3 FY2026, down 1.0% from a year earlier and down 14.8% from the prior quarter. Over 3 fiscal years it compounded at +157.6% a year.

Context

  • Total non-current assets amounted to 26.4% of total assets at the end of Q3 FY2026, down 15.1 pp from a year earlier.
  • Total non-current assets increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current assets keeps falling in the next quarterly balance sheet after a -1.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$420.81M-14.8% QoQ
Last fiscal yearDec 2025
$432.49M+3716.9% YoY
Year agoSep 2025
$425.26M-1.0% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.0%——
1 year+3716.9%——
3-year CAGR+157.6%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

USD · from the balance sheet

Latest · FY2025
432.49M USD
Year-over-year change
+3716.9%
4-year CAGR
+72.7%

Total Non-current Assets vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -1.0% is the 4th highest of 9, against a peer median of -10.9%.
  • Total non-current assets amounts to 26.4% of total assets for TGTX, versus a peer median of 12.1%.
TGTX Competitors
Total Non-current Assets for TGTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GMABGenmab A/SJun 2026$9.71B USD+280.4%+73.7%77.6%
TGTXTG Therapeutics, Inc.Sep 2026$420.81M USD-1.0%+157.6%26.4%
XNCRXencor, Inc.Jun 2026$201.75M USD-44.9%+17.3%27.8%
CLDXCelldex Therapeutics, Inc.Sep 2026$57.8M USD+31.1%+11.3%8.0%
MGNXMacroGenics, Inc.Mar 2026$35.35M USD-16.8%-18.2%16.2%
IPHAInnate Pharma S.A.Dec 2025€16M EUR-36.8%-38.3%25.5%
ADCTADC Therapeutics S.A.Mar 2026$14.73M USD+1.2%-33.0%5.1%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$13.25M USD-5.0%-19.3%5.2%
ADAGAdagene Inc.Dec 2025$888.13K USD-40.4%-34.0%1.1%
Peer median (excluding TGTX) —-10.9%-18.7%12.1%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents298.89M102.3M92.93M179.89M79.15M
Short-term Investments15.88M59.37M124.58M131.11M62.82M
Net Receivables1.39M051.09M129.19M305.63M
Inventory0039.82M110.46M125.59M
Other Current Assets2.88M2.36M5.34M15.72M57.58M
Total Current Assets330.97M168.27M317.94M566.36M630.76M
Property, Plant & Equipment (Net)11.07M10.82M8.15M7.15M6.28M
Goodwill799K799K799K00
Intangible Assets00000
Long-term Investments35.53M12.4M1.29M808K59.14M
Tax Assets0000348M
Other Non-current Assets1.26M1.27M1.42M3.37M19.08M
Total Non-current Assets48.66M25.3M11.64M11.33M432.49M
Total Assets379.63M193.57M329.59M577.69M1.06B
Account Payables0000107.51M
Short-term Debt975K0001.04M
Tax Payables00000
Deferred Revenue00152K11.41M21.23M
Other Current Liabilities62.97M51.62M52.12M78.11M23.97M
Total Current Liabilities65.38M53.2M53.72M90.68M153.76M
Long-term Debt66.79M71.14M100.12M244.43M252.67M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)457K305K6.02M12.09M8.81M
Other Non-current Liabilities0000(7.02M)
Total Non-current Liabilities77.09M81.78M115.37M264.65M261.47M
Total Liabilities142.48M134.99M169.09M355.33M415.23M
Common Stock143K146K151K156K159K
Retained Earnings(1.33B)(1.53B)(1.55B)(1.53B)(1.08B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity237.15M58.59M160.5M222.36M648.02M
Total Debt79.05M83.06M110.8M253.72M260.73M
Net Debt(219.84M)(19.24M)17.86M73.83M181.58M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.